Halozyme licenses Enhanze for $135 million

Halozyme Therapeutics Inc. (Nasdaq: HALO) licensed its Enhanze technology to Bristol-Myers Squibb (NYSE: BMY) for $105 million upfront and Roche for $30 million upfront. Shares of Halozyme soared $2.80 to close at $15.98 while Bristol-Myers stock added 22 cents to close at $62.70.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.